QuantLogix Private Company Profile

← Back to list

Viz.ai

AI-powered care coordination platform for time-sensitive medical conditions
Healthcare 📍 San Francisco, CA Founded 2016
Current Valuation
$1.2B
as of 2022-Q2
UNICORN
Viz.ai operates a clinical AI platform that detects time-sensitive conditions — large-vessel-occlusion stroke, pulmonary embolism, aortic aneurysm — on CT and MRI scans and instantly mobilizes specialist care teams. The company was valued at $1.2 billion in its 2022 Series D and has expanded across more than 1,500 U.S. hospitals. Sacra estimates roughly $40M in 2023 revenue with around 74% year-over-year growth, positioning Viz.ai as a frequently cited 2026 IPO candidate in healthcare AI.

Company Profile

CEO
Chris Mansi
Founded
2016
HQ
San Francisco, CA
Employees
~400
Total Raised
$250M
Est. Revenue
$40M (2023)
Growth
~74% YoY
Last Round
Series D — $100M (Apr 2022) · Lead: Tiger Global
IPO Status
rumored

Founders & Key People

Chris MansiDavid Golan

Investors

Tiger Global · Insight Partners · Kleiner Perkins · Greenoaks Capital · Threshold Ventures · GV

Products

  • Viz Stroke (LVO detection)
  • Viz Cardio (pulmonary embolism, aneurysm)
  • Viz Subdural and ICH
  • Viz Connect (care coordination)
  • Viz HCM, RV/LV

Competitors

Aidoc · RapidAI · Rad AI · Caption Health
Healthcare AIMedical ImagingStroke CareUnicorn
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q2. Refreshed quarterly.